BioAtla | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.27, beating the estimate of USD -0.2967.

EBIT: As of FY2025 Q3, the actual value is USD -13.92 M.

Research and Development Expenses

Research and development (R&D) expenses were $9.5 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024, marking a decrease of $6.9 million primarily due to lower program development costs, reduced headcount-related expenses, and lower non-cash stock-based compensation.

General and Administrative Expenses

General and administrative (G&A) expenses were $4.2 million for the quarter ended September 30, 2025, compared to $5.9 million for the same quarter in 2024, reflecting a decrease of $1.7 million due to reduced personnel costs and lower stock-based compensation expense.

Net Loss

Net loss for the quarter ended September 30, 2025 was $15.8 million, compared to a net loss of $10.6 million for the same quarter in 2024. The increase in net loss was primarily due to the absence of collaboration revenue recorded in 2024 and a $2.1 million non-cash loss on warrant liability recorded in Q3 2025.

Cash and Cash Equivalents

Cash and cash equivalents as of September 30, 2025 were $8.3 million, not including the $2 million milestone payment or any R&D funding from the collaboration.

Outlook / Guidance

BioAtla remains on track to complete a strategic transaction with a potential partner by year end. The company expects R&D expenses to decline through the remainder of 2025 as resources are concentrated on prioritized programs.